{"company":{"id":3792670,"name":"Sermonix Pharmaceuticals","domain":"sermonixpharma.com","url":"https://alion.io/company/sermonixpharma"},"section":"news","answer":"Sermonix Pharmaceuticals: 32 headlines on record, 0 headlines in the last 90 days. Its story counts 1 milestone.","figures":[{"label":"Headlines","value":"32"},{"label":"In 90 days","value":"0"},{"label":"Milestones","value":"1"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":31},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":1}],"news":[{"date":"2026-07-06","kind":"Blog","title":"Partners & Collaborations","url":"https://sermonixpharma.com/partners-collaborations/"},{"date":"2026-07-06","kind":"Blog","title":"About Expanded Access","url":"https://sermonixpharma.com/about-expanded-access/"},{"date":"2026-01-09","kind":"Blog","title":"Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker \"LONA\"","url":"https://sermonixpharma.com/athira-pharma-announces-name-change-to-leonabio-inc-with-new-ticker-lona/"},{"date":"2025-12-19","kind":"Blog","title":"Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million","url":"https://sermonixpharma.com/athira-pharma-announces-exclusive-license-to-lasofoxifene-phase-3-development-program-for-metastatic-breast-cancer-candidate-and-a-financing-for-up-to-236-million/"},{"date":"2025-12-18","kind":"Blog","title":"The Elaine 3 Study","url":"https://sermonixpharma.com/the-elaine-3-study/"},{"date":"2025-12-18","kind":"Blog","title":"The Elaine Study","url":"https://sermonixpharma.com/the-elaine-study/"},{"date":"2025-12-18","kind":"Blog","title":"The Elaine 2 Study","url":"https://sermonixpharma.com/the-elaine-2-study/"},{"date":"2025-04-28","kind":"Blog","title":"Posters & Presentations","url":"https://sermonixpharma.com/medical-meetings/"},{"date":"2025-04-11","kind":"Blog","title":"Sermonix Pharmaceuticals' Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67-suppression-in-phase-2-i-spy-2-arm-evaluating-therapy-in-neoadjuvant-breast-cancer-setting/"},{"date":"2025-03-27","kind":"Blog","title":"Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics","url":"https://sermonixpharma.com/sermonix-and-regor-announce-strategic-collaboration-to-optimize-regors-proprietary-rcard-platform-for-identification-of-novel-targets-and-therapeutics/"},{"date":"2025-01-29","kind":"Blog","title":"Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer","url":"https://sermonixpharma.com/sermonix-announces-clinical-breast-cancer-publication-of-article-examining-effects-of-lasofoxifene-versus-fulvestrant-on-urogenital-symptoms-in-patients-with-esr1-mutated-er-her2-metastatic-breast-c/"},{"date":"2024-10-21","kind":"Blog","title":"Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-to-host-oral-presentation-on-vaginal-and-sexual-health-at-rise-up-for-breast-cancer-conference/"},{"date":"2024-08-28","kind":"Blog","title":"Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-completes-enrollment-of-phase-2-i-spy-2-arm-evaluating-lasofoxifene-in-neoadjuvant-breast-cancer-setting/"},{"date":"2024-07-18","kind":"Blog","title":"Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-receives-u-s-patent-for-lasofoxifene-as-method-for-treating-aromatase-resistant-er-breast-cancer-in-the-absence-of-esr1-mutations/"},{"date":"2024-06-12","kind":"Blog","title":"Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene's Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-announces-breast-cancer-research-publication-of-paper-examining-lasofoxifenes-preclinical-effects-on-aromatase-inhibitor-resistant-non-esr1-mutated-breast-cancer/"},{"date":"2024-06-06","kind":"Blog","title":"Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-announces-chinese-approval-of-investigational-new-drug-application-for-lasofoxifene/"},{"date":"2024-05-02","kind":"Blog","title":"Sermonix Pharmaceuticals Announces 'Menopause' Journal Publication of Article on Oral Lasofoxifene's Effects on Vaginal Atrophy in Postmenopausal Women","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-announces-menopause-journal-publication-of-article-on-oral-lasofoxifenes-effects-on-vaginal-atrophy-in-postmenopausal-women/"},{"date":"2024-04-22","kind":"Blog","title":"Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape","url":"https://sermonixpharma.com/sermonix-to-host-kol-fireside-chat-on-advancements-in-the-metastatic-breast-cancer-treatment-landscape/"},{"date":"2024-02-14","kind":"Blog","title":"Sermonix Pharmaceuticals Announces MBC Alliance Membership, New 'Discover ELAINE' Website","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-announces-mbc-alliance-membership-new-discover-elaine-website/"},{"date":"2024-01-12","kind":"Blog","title":"Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene","url":"https://sermonixpharma.com/henlius-and-sermonix-announce-strategic-collaboration-and-exclusive-license-agreements-for-novel-endocrine-therapy-lasofoxifene/"},{"date":"2023-12-27","kind":"Blog","title":"Who is Elaine?","url":"https://sermonixpharma.com/who-is-elaine/"},{"date":"2023-12-14","kind":"Blog","title":"Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life","url":"https://sermonixpharma.com/sermonix-pharmaceuticals-shares-resuits-of-third-survey-on-esr1-and-metastatic-breast-cancer-patient-quality-of-life/"},{"kind":"News","title":"A Bench-to-Bedside Story","source":"Duke Cancer Institute","url":"https://dukecancerinstitute.org/blogs/bench-bedside-story"},{"kind":"News","title":"Phase 2 Data Support Development of Lasofoxifene in ESR1-mutant, ER+HER2 Breast Cancer","source":"onclive.com","url":"https://onclive.com/view/phase-2-data-support-development-of-lasofoxifene-in-esr1-mutant-er-her2-breast-cancer"},{"kind":"News","title":"Future Directions of Lasofoxifene Research in Breast Cancer","source":"targetedonc.com","url":"https://targetedonc.com/view/future-directions-of-lasofoxifene-research-in-breast-cancer"},{"kind":"News","title":"Emerging ESR1-Targeted Therapy Added to Abemaciclib to Treat Metastatic ER+HER2 Breast Cancer","source":"targetedonc.com","url":"https://targetedonc.com/view/emerging-esr1-targeted-therapy-added-to-abemaciclib-to-treat-metastatic-er-her2-breast-cancer"},{"kind":"News","title":"ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+HER2- Breast Cancer","source":"targetedonc.com","url":"https://targetedonc.com/view/elaine-3-study-of-lasofoxifene-initiates-for-esr1-mutated-er-her2--breast-cancer"},{"kind":"News","title":"ELAINE-1 Trial Examines Lasofoxifene in ESR1+, ER+HER2- Breast Cancer","source":"targetedonc.com","url":"https://targetedonc.com/view/elaine-1-trial-examines-lasofoxifene-in-esr1-er-her2--breast-cancer"},{"kind":"News","title":"Durable CR With Lasofoxifene in ESR1+, ER+HER2- Metastatic Breast Cancer","source":"targetedonc.com","url":"https://targetedonc.com/view/durable-cr-with-lasofoxifene-in-esr1-er-her2--metastatic-breast-cancer"},{"kind":"News","title":"Dr. Damodaran on the ELAINE-2 Trial of LasofoxifeneAbemaciclib in ESR1-Mutated, ER+HER2- Breast Cancer","source":"onclive.com","url":"https://onclive.com/view/dr-damodaran-on-the-elaine-2-trial-of-lasofoxifene-abemaciclib-in-esr1-mutated-er-her2--breast-cancer"},{"kind":"Podcast","title":"Episode #10 How to Beat Cancer by Lessons My Patients Taught Me","source":"Spotify for Creators","url":"https://creators.spotify.com/pod/profile/elliot-davidson/episodes/Episode-10-How-to-Beat-Cancer-e17tld4"}],"story":[{"title":"Founded"}],"as_of":"2026-11-17","cite":"Sermonix Pharmaceuticals, News. Alion, Nov 17, 2026. https://alion.io/company/sermonixpharma/news","html_url":"https://alion.io/company/sermonixpharma/news","json_url":"https://alion.io/company/sermonixpharma/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T10:49:37Z"}}